Posted November 2, 2009 by Cindy L. Nations
A large group status conference is scheduled for November 5, 2009 at 9 a.m. Eastern time in the Northern District of Ohio before MDL Judge Dan A. Polster. The agenda includes many important items, including discovery and expert testimony issues regarding bellwether and non-bellwether cases; pending motions; scheduling the bellwether trials; product identification updates; and status of federal/state court cooperation.
March 30, 2009 – Gadolinium is the active ingredient in several different brands of contrast dyes used to enhance MRI and MRA images and has been found to be the cause of Nephrogenic Systemic Fibrosis (NSF.) There is no known treatment for NSF, it becomes worse over time and can lead to death. View the video on how Gadolinium, known as Contrast Dye, can lead to Nephrogenic Systemic Fibrosis.
If you or someone you know has developed nephrogenic systemic fibrosis after undergoing an MRI or MRA, please contact our offices for a free case evaluation by one of our experienced pharmaceutical attorneys.